Walleye Capital’s CytomX Therapeutics CTMX Stock Holding History
Bought
Maintained
Sold
Other funds holding CTMX
KCM
Walleye Capital's CTMX Position: Q3 2026 in Review
Walleye Capital sold out of CytomX Therapeutics (CTMX) in Q3 2026, closing a stake of 126,526 shares — an estimated $474K sold.
Walleye Capital first reported a position in CTMX in Q4 2019 and held it in 5 quarters. The position peaked at $585K in Q4 2019. 194 funds tracked by Wall St. Rank hold CTMX as of Q3 2026.
- Walleye Capital reported no remaining CytomX Therapeutics position as of Q3 2026 after selling out during the quarter.
- Walleye Capital sold 126,526 CytomX Therapeutics shares in Q3 2026, an estimated $474K.
- Walleye Capital first reported a position in CytomX Therapeutics in Q4 2019 and held it in 5 quarters.
- Walleye Capital's CytomX Therapeutics position peaked at $585K in Q4 2019.
- 194 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q3 2026.
Based on Walleye Capital's 13F filing for Q3 2026, filed 13 Nov 2026.